Clinical Trials Browser

Phase 2 × Active not recruiting × mirvetuximab soravtansine × Clear all

NCT05456685 2025-10-28

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Phase 2 Active not recruiting

18 enrolled 17 charts

Endometrial Neoplasms

NCT04274426 2025-04-06

MIROVA

Phase 2 Active not recruiting

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma